Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9065-9078

  Hwang, Ju Ae ^a,c   Yang, Heung Mo ^a   Hong, Doo Pyo ^a   Joo, Sung Yeon ^a,b   Choi, Yoon La ^a   Park, Joo Hung ^c   Lazar, Alexander J ^d   Pollock, Raphael E ^e   Lev, Dina ^d   Kim, Sung Joo ^a  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Changwon National University   (South Korea)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

2 DE; Gankyrin; Liposarcoma; Predictive factor; Tumorigenesis

Indexed keywords

GANKYRIN; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MTOR PROTEIN, HUMAN; PROTEASOME; PROTEIN KINASE B; PSMD10 PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PREDICTIVE VALUE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL MOTION; CELL TRANSFORMATION; DRUG SCREENING; GENETICS; HEK293 CELL LINE; LIPOSARCOMA; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; HEK293 CELLS; HUMANS; LIPOSARCOMA; MICE; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910052443     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2375     Document Type: Article

References (46)

1. Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer. 1995; 75(1 Suppl):211-244.
2. Clark MA, Fisher C, Judson I and Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005; 353(7):701-711.
3. Sirvent N, Forus A, Lescaut W, Burel F, Benzaken S, Chazal M, Bourgeon A, Vermeesch JR, Myklebost O, Turc-Carel C, Ayraud N, Coindre JM and Pedeutour F. Characterization of centromere alterations in liposarcomas. Genes Chromosomes Cancer. 2000; 29(2):117-129.
4. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O and Turc-Carel C. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer. 1999; 24(1):30-41.
5. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagace R, Aurias A, Hostein I and Coindre JM. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005; 29(10):1340-1347.
6. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, Ranchere-Vince D, Terrier P and Pedeutour F. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007; 31(10):1476-1489.
7. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT and Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009; 62(12):1127-1135.
8. Dalal KM, Kattan MW, Antonescu CR, Brennan MF and Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006; 244(3):381-391.
9. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and Gronchi A. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer. 2008; 113(7):1657-1665.
10. Singer S, Antonescu CR, Riedel E and Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003; 238(3):358-370; discussion 370-351.
11. Dawson S, Apcher S, Mee M, Higashitsuji H, Baker R, Uhle S, Dubiel W, Fujita J and Mayer RJ. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome. J Biol Chem. 2002; 277(13):10893-10902.
12. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, Masuda T, Dawson S, Shimada Y, Mayer RJ and Fujita J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005; 8(1):75-87.
13. Qiu W, Wu J, Walsh EM, Zhang Y, Chen CY, Fujita J and Xiao ZX. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells. Oncogene. 2008; 27(29):4034-4043.
14. Higashitsuji H, Higashitsuji H, Liu Y, Masuda T, Fujita T, Abdel-Aziz HI, Kongkham S, Dawson S, John Mayer R, Itoh Y, Sakurai T, Itoh K and Fujita J. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. Biochem Biophys Res Commun. 2007; 363(3):879-884.
15. Man JH, Liang B, Gu YX, Zhou T, Li AL, Li T, Jin BF, Bai B, Zhang HY, Zhang WN, Li WH, Gong WL, Li HY and Zhang XM. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J Clin Invest. 2010; 120(8):2829-2841.
16. Iwai A, Marusawa H, Kiuchi T, Higashitsuji H, Tanaka K, Fujita J and Chiba T. Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation. J Gastroenterol. 2003; 38(8):751-758.
17. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M and Wang H. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology. 2005; 128(7):2029-2041.
18. Dai RY, Chen Y, Fu J, Dong LW, Ren YB, Yang GZ, Qian YW, Cao J, Tang SH, Yang SL and Wang HY. p28GANK inhibits endoplasmic reticulum stress-induced cell death via enhancement of the endoplasmic reticulum adaptive capacity. Cell Res. 2009; 19(11):1243-1257.
19. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF and Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2002; 8(4):638-643.
20. Umemura A, Itoh Y, Itoh K, Yamaguchi K, Nakajima T, Higashitsuji H, Onoue H, Fukumoto M, Okanoue T and Fujita J. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology. 2008; 47(2):493-502.
21. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK and Antonescu CR. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007; 67(14):6626-6636.
22. Brill E, Gobble R, Angeles C, Lagos-Quintana M, Crago A, Laxa B, Decarolis P, Zhang L, Antonescu C, Socci ND, Taylor BS, Sander C, Koff A and Singer S. ZIC1 overexpression is oncogenic in liposarcoma. Cancer Res. 2010; 70(17):6891-6901.
23. Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, Lopez-Terrada DH, Oliveira AM, Lazar AJ and Lev D. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011; 91(3):392-403.
24. Ortiz CM, Ito T, Tanaka E, Tsunoda S, Nagayama S, Sakai Y, Higashitsuji H, Fujita J and Shimada Y. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. Int J Cancer. 2008; 122(2):325-332.
25. Li X, Zhang Y, Xiong C, Jin H, Jing B, Zhang Y and Fan D. Overexpression of a new gene P28GANK confers multidrug resistance of gastric cancer cells. Cancer Invest. 2009; 27(2):129-139.
26. Zagars GK, Goswitz MS and Pollack A. Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1996; 36(2):311-319.
27. Pearlstone DB, Pisters PW, Bold RJ, Feig BW, Hunt KK, Yasko AW, Patel S, Pollack A, Benjamin RS and Pollock RE. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer. 1999; 85(1):85-92.
28. Linehan DC, Lewis JJ, Leung D and Brennan MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol. 2000; 18(8):1637-1643.
29. Kim HS, Lee J, Yi SY, Jun HJ, Choi YL, Ahn GH, Seo SW, Lim do H, Ahn YC, Park JO and Kim SJ. Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer. 2009; 9:205.
30. Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD and Tallini G. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000; 190(5):531-536.
31. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010; 42(8):715-721.
32. Crago AM and Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011; 23(4):373-378.
33. Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, Brennan MF and Singer S. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004; 240(4):686-695; discussion 695-687.
34. Fabre-Guillevin E, Coindre JM, Somerhausen Nde S, Bonichon F, Stoeckle E and Bui NB. Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas. Cancer. 2006; 106(12):2725-2733.
35. Shimoji T, Kanda H, Kitagawa T, Kadota K, Asai R, Takahashi K, Kawaguchi N, Matsumoto S, Hayashizaki Y, Okazaki Y and Shinomiya K. Clinico-molecular study of dedifferentiation in well-differentiated liposarcoma. Biochem Biophys Res Commun. 2004; 314(4):1133-1140.
36. Horvai AE, DeVries S, Roy R, O'Donnell RJ and Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009; 22(11):1477-1488.
37. Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX, Dai RY, Ren YB, Fu J and Wang HY. The oncoprotein p28GANK establishes a positive feedback loop in beta-catenin signaling. Cell Res. 2011; 21(8):1248-1261.
38. Pipas JM and Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol. 2001; 11(1):23-30.
39. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810):307-310.
40. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602.
41. Tang S, Yang G, Meng Y, Du R, Li X, Fan R, Zhao L, Bi Q, Jin J, Gao L, Zhang L, Li H, Fan M, Wang Y, Wu K, Liu J, et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther. 2010; 9(2):88-95.
42. McCormick F. Signalling networks that cause cancer. Trends Cell Biol. 1999; 9(12):M53-56.
43. Luo J, Manning BD and Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-262.
44. Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, Ren YB, Su B, Cao GW, Yang Y, Yan YQ, Shen F, Wu MC, Feng GS and Wang HY. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology. 2011; 53(1):181-192.
45. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP and Cordon-Cardo C. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007; 13(6):748-753.
46. Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, Grebliunaite R, Ou WB, Sicinska E, Raut CP, Demetri GD, Perez-Atayde AR, Wagner AJ, Fletcher JA, Fletcher CD and Look AT. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011; 108(39):16386-16391.